"Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine.
Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes.
Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer.
By viewing the human body through the lens of physics a new realm of possibilities has emerged."
Laurent Levy, CEO of Nanobiotix
2003Creation of the Company as a spin-off from the University of Buffalo in New York (United States).
2007-2010Development of the NanoXray research program.
2011Authorization of Affsaps (formerly ANSM) to start the first phase I / II (pilot) clinical study in humans and start of the treatment of the first patient recruited in the study.
2012Public listing on the Euronext Paris market.
Partnership with PharmaEngine.
2014Creation of the Company's first US subsidiary in Cambridge, Massachusetts.
2015Start of the first clinical trial in the United States with NBTXR3 in Prostate Cancer.
2016Filing of the CE Marking Application for NBTXR3 in Soft Tissue Sarcoma.
2017Opening of a new facility to expand manufacturing capabilities, increase production capacity and prepare for commercialization.
FDA approval of Nanobiotix’s first immuno-oncology trial in the US. Opening of two new affiliates in Germany and Spain.
2018Launch of a non-dilutive financial partnership with the European Investment Bank (EIB) to borrow up to 40M€ .
Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma.
2019Launch of collaboration with the University of Texas MD Anderson Cancer Center for nine new phase I/II clinical trials, treating six cancer indications and involving 340 patients.
Achievement of European market approval (CE marking) for NBTXR3 ( Hensify®) in the treatment of locally advanced Soft Tissue Sarcoma.
Incorporation of the Company’s spinoff, Curadigm
2020Granted Fast Track designation by US FDA for investigation of NBTXR3 in head and neck cancer.
Positive first results from phase I expansion in locally advanced head and neck cancer.
First phase I trial with pancreatic cancer is safe to proceed per US FDA.
First patient injected with NBTXR3 in pancreatic cancer.
Positive first clinical data in phase I immuno-oncology trial.
Raise of approximately €20 million in placement of ordinary new shares with US and European investors.
Public listing on the Nasdaq stock exchange.
European Market Approval (CE marking) in locally advanced Soft Tissue Sarcoma
clinical trials in several types of cancer
patents issued or in process of being issued
Clinical trials in 15 countries:
patients treated in the studies
physicians involved in clinical trials
million euros raised since its creation